Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 7Terminated 4Recruiting 3Unknown 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 68Head & Neck 43Thoracic 11Tumor-Agnostic 7CNS 5Gynecologic 4Breast 3Sarcoma 2Genitourinary 2Plasma cell 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Rectal Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Cetuximab × Gynecologic × Clear all
NCT00766142 2025-08-29

COCHISE

Institut Bergonié

Phase 2 Terminated
18 enrolled 9 charts
GastrointestinalGynecologic

Colonic Neoplasms, Peritoneal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00518193 2011-06-30

ERBUS

ARCAGY/ GINECO GROUP

Phase 2 Terminated
44 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT00082212 2010-04-09

A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Eli Lilly and Company

Phase 2 Terminated
25 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡